Core Viewpoint - Investors in Jasper Therapeutics, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of alleged misrepresentations by the company regarding its manufacturing controls and product prospects [1][3]. Summary by Sections Lawsuit Details - The lawsuit alleges that from November 30, 2023, to July 3, 2025, Jasper Therapeutics failed to disclose critical information, including the lack of necessary controls and procedures for third-party manufacturers to comply with cGMP regulations [3]. - This failure is claimed to have increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, particularly briquilimab [3]. - The lawsuit also suggests that the company's business and financial prospects were overstated, and that positive statements made by the defendants were materially misleading [3]. Participation Information - Investors who suffered losses are encouraged to contact the Law Offices of Howard G. Smith before November 18, 2025, to participate in the ongoing class action lawsuit [2][4]. - Individuals do not need to take any immediate action to be part of the class action and may choose to retain counsel or remain absent [5].

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our ...

Core Viewpoint - A class action securities lawsuit has been filed against Lineage, Inc. due to alleged securities fraud affecting investors who purchased common stock during the company's initial public offering on July 26, 2024 [1][2]. Summary by Sections Class Definition - The lawsuit aims to recover losses for investors adversely affected by the alleged fraud, specifically targeting those who purchased Lineage common stock in connection with the IPO [2]. Case Details - The complaint alleges several key points: - Lineage experienced a decline in customer demand due to increased cold-storage supply and customers destocking excess inventory from the COVID-19 pandemic [3]. - The company raised prices prior to the IPO, which could not be sustained amid weakening demand [3]. - Lineage failed to counteract adverse trends through operational efficiencies or competitive advantages [3]. - Contrary to claims of stable revenue growth and high occupancy rates, the company faced stagnant or declining revenue, occupancy rates, and rent prices [3]. - Overall, Lineage's financial results and business prospects were materially impaired as a result of these issues [3]. Next Steps - Investors who suffered losses during the relevant timeframe have until September 30, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

Accessibility StatementSkip Navigation NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fluor Corporation ("Fluor Corporation" or the "Company") (NYSE: FLR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fluor Corporation investors who were adversely affected by alleged securities fraud between February 18, 2025 and July 31, 2025. Follow the link below to get more information and be contacted by a member of our team: ...

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. Accessibility StatementSkip Navigation NEW YORK, Sept. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Dow Inc. ("Dow Inc." or the "Company") (NYSE: DOW) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Dow Inc. investors who were adversely affected by alle ...

Core Viewpoint - A class action securities lawsuit has been filed against Sable Offshore Corp. due to alleged securities fraud affecting investors who purchased shares between May 19, 2025, and June 3, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who were misled by false statements regarding the company's oil production activities off the coast of California [3]. - Allegations include that Sable Offshore Corp. falsely claimed to have restarted oil production when it had not, leading to materially false and misleading statements about the company's business and operations [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 26, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5].

Core Viewpoint - Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW) [1]. Group 1: Company Overview - Edwards Lifesciences Corporation is under scrutiny for possible fiduciary duty violations by its leadership [1]. Group 2: Legal Context - Rosen Law Firm specializes in securities class actions and shareholder derivative litigation, emphasizing the importance of selecting qualified legal counsel with a successful track record [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time and over $438 million secured for investors in 2019 alone [3].

Core Viewpoint - A class action lawsuit has been filed against Quantum Corporation for violations of the Securities Exchange Act due to false and misleading statements regarding revenue recognition [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from November 15, 2024, to August 18, 2025, with a deadline for lead plaintiff appointments set for November 3, 2025 [2]. - Quantum Corporation was required to restate prior financial statements because of improper revenue recognition, leading to claims that its public statements were materially misleading [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not necessary to participate in any recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress at no cost [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for alleged violations of securities laws, specifically related to misleading statements regarding its Biologics License Application (BLA) for MOLBREEVI [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from March 7, 2024, to May 23, 2025, with a deadline for lead plaintiff appointments set for November 10, 2025 [2]. - The complaint alleges that Savara made false and misleading statements to the market, particularly regarding the adequacy of information provided in its BLA submitted to the FDA [2]. - It is claimed that the FDA was unlikely to approve Savara's BLA due to deficiencies in the information provided, which rendered the company's public statements materially misleading throughout the class period [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not a requirement for recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's status, with no cost or obligation to participate [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].

Core Viewpoint - Investors in Sable Offshore Corp. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's oil production activities [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit claims that between May 19, 2025, and June 3, 2025, Sable Offshore Corp. failed to disclose that it had not restarted oil production off the coast of California, despite representations to the contrary [2]. - The positive statements made by the defendants about the company's business and prospects were deemed materially misleading and lacked a reasonable basis during this period [2]. Participation Information - Investors who suffered losses on their Sable investments are encouraged to participate in the lawsuit, with a lead plaintiff deadline set for September 26, 2025 [2]. - Interested parties can contact Glancy Prongay & Murray LLP for more information or to learn about their rights regarding this matter [3][4].